U.S. Markets closed
  • S&P 500

    +58.48 (+1.44%)
  • Dow 30

    +415.12 (+1.26%)
  • Nasdaq

    +208.43 (+1.74%)
  • Russell 2000

    +34.10 (+1.93%)
  • Crude Oil

    +1.33 (+1.79%)
  • Gold

    -10.70 (-0.54%)
  • Silver

    +0.25 (+1.03%)

    -0.0062 (-0.5640%)
  • 10-Yr Bond

    -0.0570 (-1.61%)
  • Vix

    -0.32 (-1.68%)

    -0.0058 (-0.4686%)

    +0.1080 (+0.0814%)

    -71.81 (-0.25%)
  • CMC Crypto 200

    +7.58 (+1.23%)
  • FTSE 100

    +11.31 (+0.15%)
  • Nikkei 225

    +258.55 (+0.93%)

Canna-Pet(R) Announces Launch of New MaxCBD Canna-Biscuits

Up to Six Times More CBD in Every Biscuit

BOULDER, CO--(Marketwired - Apr 2, 2015) - Peak Pharmaceuticals, Inc. (OTCQB: PKPH) (the "Company"), and Canna-Pet, a leading innovator of non-prescription cannabinoid products for animals, are delighted to announce the launch of the all new MaxCBD dog biscuits, which offer up to six times the CBD of the standard Canna-Biscuit product line. The new product is now available online at https://canna-pet.com/product/canna-biscuits-for-dogs-maxcbd-maple-bacon/.

The limited edition MaxCBD Canna-Biscuits are available in the highly popular Maple Bacon flavor and include the Company's proprietary Canna-Pet® formulation. Canna-Pet® is formulated to deliver the entire cannabinoid profile of hemp, including CBD, as well as the hemp based terpenes. Canna-biscuits are made in the USA, with 100% organic, non-GMO, human grade food ingredients, and the bite-sized treats are easy to administer at home or on the go. With this latest product addition, Peak Pharma now offers six different biscuit types as well as seven different Canna-Pet® capsule products for pets.

Our new Maximum CBD biscuits are for those who seek the highest CBD and cannabinoid content for their pets. MaxCBD biscuits are safe to administer and we encourage visiting our website for our guidelines on serving size. Please always consult your veterinarian before using any supplements.

Company CEO, Dr. Soren Mogelsvang States, "Our new MaxCBD Canna-Biscuit category will be an interesting test of consumer interest in serving size and ease of use. If our limited edition biscuits perform well with our consumers, we plan to roll out additional flavors as quickly as possible."

About Canna-Pet® Products for Pet Health
Canna-Pet® offers non-prescription CBD products for domesticated animals such as cats and dogs. Canna-Pet® is the culmination of years of research and development to provide the benefits of hemp-based CBD and cannabinoids without the "high" typically associated with psychoactive components. The company uses non-GMO hemp as starting material and all products are proudly manufactured in the USA. In addition to CBD, Canna-Pet products differ from its competitors through the use of proprietary ratios of hemp derived cannabinoids and terpenes. Canna-Pet® is a trademarked, leading producer of safe, hemp-based, cannabinoid (CBD) containing products, which are available under an exclusive commercial license agreement with Peak Pharmaceuticals, Inc. (OTCQB: PKPH). Order online at: www.canna-pet.com or under "Pet Supplies" on Amazon, and join us on Facebook and Twitter.

Additional details of Peak Pharmaceuticals business, finances, appointments, risks and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov. For more information please visit www.peakpharma.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the U.S. Food and Drug Administration (USFDA). The products mentioned herein are not intended for human consumption, or to diagnose, treat, cure, or prevent any disease. Information contained or made available through the Canna-Pet™ website or affiliate sites is not intended to constitute or substitute for legal or veterinary advice.